Implementation of evidence based cardiovascular risk treatments by general practitioners

New Zealand Medical Journal

Volumn 114, Issue 1133, 2001, Pages 260-262

  Crossen, Kendall ^c   Scott, Russell S ^a   McGeoch, Graham R B ^a   George, Peter M ^b  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b CANTERBURY HEALTH LABORATORIES   (New Zealand)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

AGED; ANAMNESIS; ARTICLE; CORONARY ARTERY DISEASE; EVIDENCE BASED MEDICINE; FEMALE; GENERAL PRACTICE; HUMAN; LIFESTYLE; MALE; MEDICAL AUDIT; RISK FACTOR;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANTILIPEMIC AGENTS; ASPIRIN; CORONARY DISEASE; EVIDENCE-BASED MEDICINE; FAMILY PRACTICE; FEMALE; HUMANS; LIFE STYLE; MALE; MEDICAL AUDIT; MEDICAL HISTORY TAKING; RISK FACTORS;

EID: 0035827653     PISSN: 00288446     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Daly LE. Long term effect on mortality of stopping smoking after unstable angina and myocardial infarction. BMJ 1983; 287: 324-6.
2. Expert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Executive summary of the clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults. Arch Intern Med 1998; 158: 1855-97.
3. Singh R, Rastogi S, Verma R et al. Randomised controlled trial of cardioprotective diet in patients with recent acute MI: results of one year follow up. BMJ 1992; 304: 1015-9.
4. O'Connor G, Buring J, Yusuf S et al. An overview of randomised trials of rehabilitation with exercise after MI. Circulation 1989; 80: 234-44.
5. Silagy C, Muir J, Couler A et al. Lifestyle advice in general practice: rates recalled by patients. BMJ 1992; 305: 871-4.
6. Campbell N, Thain J, Deans G et al. Secondary prevention in coronary heart disease: baseline survey of provision in general practice. BMJ 1998; 316: 1430-4.
7. Antiplatelet Trialist Collaboration. Collaboration overview of randomised trials of antiplatelet therapy I: prevention of death, MI and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
8. Yusuf S, Peto R, Lewis J et al. Beta-blockade during and after myocardial infarction: an overview of the randomised trials. Prog Cardiovascular Dis 1985; 27: 335-71.
9. Pfeiffer M, Braunwald E, Move L et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after MI: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669-77.
10. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high-risk patients. N Engl JMed 2000; 342: 145-53.
11. Sacks F, Pfeiffer M, Moyle L et al for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl Med L 1996; 335: 1001-9.
12. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Srudy (4S). Lancet 1995; 145: 1274-5.
13. The Long term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
14. H. Rubins H, Robins S, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol; Veternas Affairs High Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410-18.
15. Haffner S. Secondary prevention of coronary heart disease; the role of fibrates. Circulation 2000; 102: 2-4.
16. ASPIRE Steering Group. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart 1996; 75: 334-42.
17. Ellis C, Zambanini A, French J et al. Inadequate control of lipid levels in patients with a previous myocardial infarction. NZ Med J 1998; 111: 464-7.
18. Shaher E, Folsom A, Romm FJ et at. Patterns of aspirin use in middle-aged adults: The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 1996; 131: 915-22.
19. Eccles M, Bradshaw C. Use of secondary prophylaxis against myocardial infarction in the north of England. BMJ 1991; 302: 91-2.
20. Brand D, Newcomer L, Freiburger A et al. Cardiologists' practices compared with practice guidelines: use of beta-blockade after acute myocardial infarction. J Am Coll Cardiol 1995; 26: 1432-6.
21. Wang TJ, Stafford RS. National patterns and predictors of beta-blocker use in patients with coronary artery disease. Arch Intern Med 1998; 158: 1901-6.
22. Soumerai S, McLaughlin T, Spoegelman D et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997; 277: 115-21.
23. 1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia. Dyslipidaernia Advisory Group on behalf of the scientific committee of the National Heart Foundation of New Zealand. NZ Med J 1996; 109: 224-32.
24. Simons L, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs, Med J Aust 1996; 164: 208-11.